Address correspondence to Dr Jaya Trivedi, Department of Neurology & Neurotherapeutics, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390, [email protected].
RELATIONSHIP DISCLOSURE: Dr Trivedi has received personal compensation in the range of $500 to $4999 for serving on a scientific advisory or data safety monitoring board for argenx. The institution of Dr Trivedi has received research support from the National Institutes of Health (NIH).
UNLABELED USE OF PRODUCTS/INVESTIGATIONAL USE DISCLOSURE: Dr Trivedi discusses the use of acetazolamide, carbamazepine, eplerenone, flecainide, hydrochlorothiazide, lacosamide, lamotrigine, mexiletine, phenytoin, procainamide, quinine, ranolazine, rufinamide, spironolactone, tocainide, and triamterene as treatment options that are not US Food and Drug Administration (FDA) approved for the for the conditions discussed in this article.